BioLineRx (BLRX) Short term Debt (2016 - 2025)

BioLineRx's Short term Debt history runs 10 years deep, the most recent figure standing at $4.5 million for Q4 2025.

• In Q4 2025, Short term Debt changed 0.0% year-over-year to $4.5 million; the TTM figure through Dec 2025 stood at $4.5 million (changed 0.0% YoY), while the FY2025 annual figure was $4.5 million, changed 0.0% from the prior year.
• Short term Debt was $4.5 million for Q4 2025 at BioLineRx, roughly flat from $4.5 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $10.7 million in Q2 2024 to a low of $802000.0 in Q3 2022.
• Historically, Short term Debt has averaged $3.8 million across 5 years, with a median of $3.3 million in 2021.
• The sharpest annual moves came in 2022 and 2023: Short term Debt sank 77.57% in 2022, then surged 283.79% in 2023.
• A 5-year view of Short term Debt shows it stood at $2.8 million in 2021, then tumbled by 44.07% to $1.5 million in 2022, then soared by 103.96% to $3.1 million in 2023, then surged by 42.42% to $4.5 million in 2024, then changed by 0.0% to $4.5 million in 2025.
• The last three Short term Debt figures came in at $4.5 million (Q4 2025), $4.5 million (Q3 2025), and $4.5 million (Q2 2025), per Business Quant data.